Publicacións en colaboración con investigadores/as de Centro de Investigación en Red en Enfermedades Cardiovasculares (54)

2024

  1. Tratamiento de placas vulnerables funcionalmente no significativas en el IAMCEST multivaso: diseño del estudio VULNERABLE

    REC: Interventional Cardiology, Vol. 6, Núm. 4, pp. 278-286

2022

  1. Characterization of hereditary transthyretin cardiac amyloidosis in Spain

    Revista Espanola de Cardiologia, Vol. 75, Núm. 6, pp. 488-495

  2. Clinical profile and causes of death according to ejection fraction in patients with heart failure cared for in a specialized Cardiology unit

    Revista Clinica Espanola, Vol. 222, Núm. 3, pp. 152-160

  3. Extracorporeal membrane oxygenation: a life saving therapy

    REC: CardioClinics, Vol. 57, Núm. 1, pp. 1-3

  4. Genotype-phenotype correlations in hypertrophic cardiomyopathy: a multicenter study in Portugal and Spain of the TPM1 p.Arg21Leu variant

    Revista Espanola de Cardiologia, Vol. 75, Núm. 3, pp. 242-250

  5. Impact of intrapatient blood level variability of calcineurin inhibitors on heart transplant outcomes

    Revista Espanola de Cardiologia, Vol. 75, Núm. 2, pp. 129-140

  6. Infectious complications associated with short-term mechanical circulatory support in urgent heart transplant candidates

    Revista Espanola de Cardiologia, Vol. 75, Núm. 2, pp. 141-149

  7. Perfiles analíticos pre-configurados en insuficiencia cardiaca: implementación y uso en el Sistema Nacional de Salud Español

    Advances in Laboratory Medicine, Vol. 3, Núm. 1, pp. 71-78

  8. Prognostic value of a model based on IC-BERG recommendations in ambulatory patients with heart failure

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 76-84

  9. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

  10. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

  11. Results of heart retransplantation: subanalysis of the Spanish Heart Transplant Registry

    Revista Espanola de Cardiologia, Vol. 75, Núm. 1, pp. 60-66

  12. Risk stratification by magnetic resonance in chronic coronary syndrome

    Revista Espanola de Cardiologia, Vol. 75, Núm. 3, pp. 200-202

  13. Serum potassium dynamics during acute heart failure hospitalization

    Clinical Research in Cardiology, Vol. 111, Núm. 4, pp. 368-379

  14. Specific test panels for patients with heart failure: Implementation and use in the Spanish National Health System

    Advances in Laboratory Medicine, Vol. 3, Núm. 1, pp. 65-70

2021

  1. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy

    European Heart Journal, Vol. 42, Núm. 32, pp. 3063-3073

  2. Association of Left Ventricular Systolic Dysfunction among Carriers of Truncating Variants in Filamin C with Frequent Ventricular Arrhythmia and End-stage Heart Failure

    JAMA Cardiology, Vol. 6, Núm. 8, pp. 891-901

  3. Cardiovascular effects of mexiletine for treatment of myotonia in myotonic dystrophy type 1

    Revista Espanola de Cardiologia, Vol. 74, Núm. 11, pp. 986-987

  4. Chest pain unit: do not forget the clinical indexes. Response

    Revista Espanola de Cardiologia

  5. Comparison of two strategies in a chest pain unit: stress echocardiography and multidetector computed tomography

    Revista Espanola de Cardiologia, Vol. 74, Núm. 1, pp. 59-64